Cargando…
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646121/ http://dx.doi.org/10.1186/2051-1426-3-S2-P171 |
| _version_ | 1782400919147642880 |
|---|---|
| author | Rizvi, Naiyer Barlesi, Fabrice Brahmer, Julie Felip, Enriqueta Forde, Patrick Garassino, Marina Goldberg, Sarah Vansteenkiste, Johan Jarkowski, Anthony McIntosh, Stuart Zhao, Luping Antonia, Scott |
| author_facet | Rizvi, Naiyer Barlesi, Fabrice Brahmer, Julie Felip, Enriqueta Forde, Patrick Garassino, Marina Goldberg, Sarah Vansteenkiste, Johan Jarkowski, Anthony McIntosh, Stuart Zhao, Luping Antonia, Scott |
| author_sort | Rizvi, Naiyer |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4646121 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46461212015-11-20 Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC Rizvi, Naiyer Barlesi, Fabrice Brahmer, Julie Felip, Enriqueta Forde, Patrick Garassino, Marina Goldberg, Sarah Vansteenkiste, Johan Jarkowski, Anthony McIntosh, Stuart Zhao, Luping Antonia, Scott J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4646121/ http://dx.doi.org/10.1186/2051-1426-3-S2-P171 Text en Copyright © 2015 Rizvi et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Rizvi, Naiyer Barlesi, Fabrice Brahmer, Julie Felip, Enriqueta Forde, Patrick Garassino, Marina Goldberg, Sarah Vansteenkiste, Johan Jarkowski, Anthony McIntosh, Stuart Zhao, Luping Antonia, Scott Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title | Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title_full | Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title_fullStr | Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title_full_unstemmed | Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title_short | Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
| title_sort | phase iii, randomized, open-label study of durvalumab (medi4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic nsclc: mystic |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646121/ http://dx.doi.org/10.1186/2051-1426-3-S2-P171 |
| work_keys_str_mv | AT rizvinaiyer phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT barlesifabrice phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT brahmerjulie phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT felipenriqueta phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT fordepatrick phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT garassinomarina phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT goldbergsarah phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT vansteenkistejohan phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT jarkowskianthony phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT mcintoshstuart phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT zhaoluping phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic AT antoniascott phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736incombinationwithtremelimumabordurvalumabaloneversusplatinumbasedchemotherapyinfirstlinetreatmentofpatientswithadvancedmetastaticnsclcmystic |